References
- Cameron AJ, Lomboy CT. Barrett's esophagus: age, prevalence, and extent of columnar epithelium. Gastroenterology 1992; 103: 1241–5
- Bonino JA, Sharma P. Barrett's esophagus. Curr Opin Gastroenterol 2005; 21: 461–5
- Fitzgerald RC. Barrett's oesophagus and oesophageal adenocarcinoma: how does acid interfere with cell proliferation and differentiation?. Gut 2005; 54 Suppl 1: i21–6
- Jankowski JA, Harrison RF, Perry I, Balkwill F, Tselepis C. Barrett's metaplasia. Lancet 2000; 356: 2079–85
- Fein M, Maroske J, Fuchs KH. Importance of duodenogastric reflux in gastro-oesophageal reflux disease. Br J Surg 2006; 93: 1475–82
- Kaur BS, Triadafilopoulos G. Acid- and bile-induced PGE(2) release and hyperproliferation in Barrett's esophagus are COX-2 and PKC-epsilon dependent. Am J Physiol Gastrointest Liver Physiol 2002; 283: G327–34
- Guo RJ, Suh ER, Lynch JP. The role of Cdx proteins in intestinal development and cancer. Cancer Biol Ther 2004; 3: 593–601
- Moons LM, Bax DA, Kuipers EJ, Van Dekken H, Haringsma J, Van Vliet AH, et al. The homeodomain protein CDX2 is an early marker of Barrett's oesophagus. J Clin Pathol 2004; 57: 1063–8
- Silberg DG, Sullivan J, Kang E, Swain GP, Moffett J, et al. Cdx2 ectopic expression induces gastric intestinal metaplasia in transgenic mice. Gastroenterology 2002; 122: 689–96
- Kazumori H, Ishihara S, Rumi MA, Kadowaki Y, Kinoshita Y. Bile acids directly augment caudal related homeobox gene Cdx2 expression in oesophageal keratinocytes in Barrett's epithelium. Gut 2006; 55: 16–25
- Tonra JR, Hicklin DJ. Targeting the vascular endothelial growth factor pathway in the treatment of human malignancy. Immunol Invest 2007; 36: 3–23
- Zhong H, Bowen JP. Antiangiogenesis drug design: multiple pathways targeting tumor vasculature. Curr Med Chem 2006; 13: 849–62
- Harrison RF, Perry I, Jankowski JA. Barrett's mucosa: remodelling by the microenvironment. J Pathol 2000; 192: 1–3
- Couvelard A, Paraf F, Gratio V, Scoazec JY, Henin D, Degott C, et al. Angiogenesis in the neoplastic sequence of Barrett's oesophagus. Correlation with VEGF expression. J Pathol 2000; 192: 14–8
- Jenkins GJ, Harries K, Doak SH, Wilmes A, Griffith AP, Baxter JN, et al. The bile acid deoxycholic acid at neutral pH activates NF. kappaB and induces IL-8 expression in esophageal cells in vitro. Carcinogenesis 2004; 25: 317–23
- Phillips RW, Frierson HF, Jr, Moskaluk CA. Cdx2 as a marker of epithelial intestinal differentiation in the esophagus. Am J Surg Pathol 2003; 27: 1442–7
- Todd JA, Basu KK, de Caestecker JS. Normalization of oesophageal pH does not guarantee control of duodenogastro-oesophageal reflux in Barrett's oesophagus. Aliment Pharmacol Ther 2005; 21: 969–75
- Konturek PC, Burnat G, Hahn EG. Bile salts induce COX-2 expression in Barrett adenocarcinoma cells via stimulation of NFkB [abstract I-P-14-83]. Digestion 2006; 73 Suppl 2: 49
- Dvorak K, Payne CM, Chavarria M, Ramsey L, Dvorakova B, Bernstein H, et al. Bile acids in combination with low pH induce oxidative stress and oxidative DNA damage: relevance to the pathogenesis of Barrett's oesophagus. Gut 2007; 56: 763–771
- Mobius C, Stein HJ, Becker I, Feith M, Theisen J, Gais P, et al. The “angiogenic switch” in the progression from Barrett's metaplasia to esophageal adenocarcinoma. Eur J Surg Oncol 2003; 29: 890–4
- Wali RK, Stoiber D, Nguyen L, Hart J, Sitrin MD, Brasitus T, et al. Ursodeoxycholic acid inhibits the initiation and post-initiation phases of azoxymethane-induced colonic tumor development. Cancer Epidemiol Biomarkers Prev 2002; 11: 1316–21